CareDx (CDNA) Earnings: Q3 2026 Results

The quarter ended September 30, 2026 and CareDx published the results on October 29, 2026. Revenue and diluted EPS are shown against Q3 2025, the same quarter a year earlier, which takes seasonal swings out of the comparison. CareDx reports EPS two ways: GAAP, under the accounting rules every US filer follows, and non-GAAP, which leaves out items the company considers outside its operating results. The release reconciles the two, and when they diverge, the reconciliation says why.

• CareDx sold its Lab Products business on June 30, 2026, so Q3 2026 has no product revenue. Q3 2025 included $12.5 million of it.
• CareDx acquired Naveris, Inc., maker of the NavDx test, on July 1, 2026. Q3 2026 Testing Services revenue includes $12 million of Specialty Oncology revenue that Q3 2025 did not have.
• Q2 2026 GAAP diluted EPS of $2.07 includes a $113.0 million gain on the sale of the Lab Products business.

Source: CareDx Q3 2026 results, October 29, 2026. Also in the Form 10-Q for the quarter ended September 30, 2026. Figures as reported; checked against the release on November 10, 2026.

How CareDx splits revenue in its own release, under its own labels, for Q3 2026 against Q3 2025. Indented lines are parts of the line above them.

• CareDx's Testing services revenue revenue was $119 million in Q3 2026, up 65% from $72.2 million in Q3 2025, 86% of total revenue.
• CareDx's Patient and digital solutions revenue revenue was $20.2 million in Q3 2026, up 31% from $15.4 million in Q3 2025, 14% of total revenue.

Segment lines are the figures writers cite most often, because they show where the growth in a quarter came from. Companies redraw their segments from time to time and restate the prior year to match, so a year-ago figure here can differ from the one printed a year ago. When that has happened, the note above says so.

From the earnings release

In its Q3 2026 release, CareDx said:

“For the full year 2026, CareDx now expects revenue to be in the range of $520 million to $530 million, compared with its previously disclosed range of $490 million to $500 million.”

“The Company now expects full-year 2026 Adjusted EBITDA to be in the range of $90 million to $100 million, compared with its previously disclosed range of $66 million to $78 million.”

Source: CareDx Q3 2026 release, Oct 29, 2026.

This is the company's own guidance as of Oct 29, 2026, quoted as given. Walnut does not make forecasts of its own. Analyst estimates for the coming quarters are on the CDNA forecast page.

Revenue and diluted EPS for the last 5 quarters. Each date links to that quarter's release.

Total revenue and GAAP diluted EPS, each as first reported in that quarter's release.

We do not hold a confirmed date for CareDx's next report. Companies post the date on their investor relations site a few weeks ahead, usually with the time of the conference call.

Each quarter keeps its own page with the figures as reported, so a link to one stays pointed at the same numbers after the next report.

• Q3 2026 (this page), reported Oct 29, 2026

CareDx earns most of its revenue from molecular tests for transplant patients, such as AlloSure and AlloMap, and now from the NavDx cancer test. Testing services revenue was $119.2 million of Q3 2026 total revenue of $139.4 million, up 65% from $72.2 million. Patient and digital solutions, mainly the CareDx Pharmacy and transplant software such as Ottr, added $20.2 million, up 31%. (CareDx Q3 2026 release, Oct 29, 2026; CareDx Form 10-Q, Q3 2026, Oct 29, 2026; CareDx Form 10-K, 2025, Feb 25, 2026)

Two deals change the comparison. CareDx sold its Lab Products business on June 30, 2026, removing $12.5 million of product revenue that was in Q3 2025, and bought Naveris, maker of NavDx, on July 1, 2026 for $160 million in cash and up to $100 million in contingent consideration. NavDx brought $12 million of Specialty Oncology revenue into the quarter. (CareDx Q3 2026 release, Oct 29, 2026)

Testing Services volume was about 75,900 tests, up 51%. The quarter also included $15 million of revenue for tests performed in earlier periods, against $6 million a year earlier. Excluding those catch-up amounts, CareDx said Testing Services revenue rose about 58%. (CareDx Q3 2026 release, Oct 29, 2026)

Medicare is CareDx's largest payer. About 31% of total revenue came from Medicare in Q3 2026, against 32% a year earlier, and 25% of accounts receivable was due from Medicare at September 30, 2026. In 2025 about 46% of testing services revenue came from Medicare. (CareDx Form 10-Q, Q3 2026, Oct 29, 2026; CareDx Form 10-K, 2025, Feb 25, 2026)

CareDx earned $19.3 million in Q3 2026, or $0.35 per diluted share, against $1.7 million, or $0.03, a year earlier. Income from operations was $8.1 million. Net income was higher than pretax income because of an $8.6 million income tax benefit, which CareDx said came primarily from releasing part of its valuation allowance in connection with the Naveris acquisition. (CareDx Q3 2026 release, Oct 29, 2026; CareDx Form 10-Q, Q3 2026, Oct 29, 2026)

Non-GAAP diluted EPS was $0.70, against $0.28. CareDx's non-GAAP figures add back stock-based compensation ($9.7 million), business development and portfolio optimization expense tied to the Lab Products sale and the Naveris deal ($5.5 million) and amortization of acquired intangibles ($3.9 million). The $8.6 million tax benefit is not removed, so it is in both the GAAP and non-GAAP figures. (CareDx Q3 2026 release, Oct 29, 2026)

Diluted weighted average shares were 54,984,989 against 53,736,790 a year earlier. Q2 2026 GAAP net income was $110.6 million because it included a $113.0 million gain on the sale of the Lab Products business. (CareDx Q3 2026 release, Oct 29, 2026)

Diluted EPS divides net income by the weighted average number of shares outstanding in the quarter, plus the shares that options and other equity awards could add. Buybacks shrink that count and lift EPS for the same profit; share issuance and stock awards enlarge it.

CareDx gives full-year revenue and Adjusted EBITDA ranges in its release. With Q3 results it expects 2026 revenue of $520 million to $530 million, up from $490 million to $500 million, and Adjusted EBITDA of $90 million to $100 million, up from $66 million to $78 million. (CareDx Q3 2026 release, Oct 29, 2026)

CareDx said it is preparing a first-quarter 2027 commercial launch of AlloHeme and broader commercial availability of HistoMap Kidney in 2027, with both programs targeting CLIA readiness before year-end. (CareDx Q3 2026 release, Oct 29, 2026)

A consensus figure is the average of the models published by the analysts who cover CareDx, collected by a data provider and revised up to the day of the report. A quarter that lands above it says how expectations were set as much as how the business did, and the share price on the day also reflects the guidance and the lines no consensus covers.

The consensus figures on this page are Yahoo Finance's, as pulled on the date shown. Each comes with the number of analysts behind it; the smaller that number, the more one revised estimate can move the average.

The figures below are the ones CareDx's own release and filings put weight on for Q3 2026, with the latest reported value for each.

What the quarter means for a holding is a separate question from what it reported. The case for and against owning CDNA is on is CDNA a buy or a sell?, what analysts expect next is on the CDNA forecast, and what the company does is on the CareDx (CDNA) stock page.

Every number on this page can be traced to a document CareDx published. Checking one takes a couple of minutes, and it is worth doing before you quote a figure anywhere.

• The results release is the document linked in the source line above. Companies publish it on their investor relations site at the moment results go out, and it carries the headline tables: revenue, operating income, net income and EPS for the quarter and the year-ago quarter.
• The same release is filed with the SEC as Exhibit 99.1 to a Form 8-K under Item 2.02, usually on the day of the report. The SEC copy does not change after the fact, which makes it the safer thing to link when you cite a number.
• The quarterly report (Form 10-Q) follows within a few weeks and carries the full financial statements, the segment note and management's discussion of what changed. The fourth quarter is covered by the annual report (Form 10-K) instead.
• Restated comparisons are flagged in the notes on this page. When a company redraws its segments or changes how it adjusts EPS, it restates the year-ago column, so the year-ago figure in a new release can differ from the one printed a year ago. This page always uses the comparison in the newer release, because that is the like-for-like one.

A walk-through of every line in a release, with what each one tells you, is in how to read an earnings report.